The first angiogenesis inhibitor has recently been approved for cancer treatment. Nonetheless, optimizing the dose of novel angiogenesis inhibitors remains a formidable challenge-primarily because we lack reliable surrogate markers of tumor anglogenesis. In this issue, Shaked et al. provide evidence that the levels of circulating endothelial precursor cells (CEPs), which contribute to the formation of tumor vessels, are genetically predetermined and regulated by angiogenic factors, and reflect the antitumor efficacy of angiogenesis inhibitors. These findings highlight the potential usefulness of CEPs as a surrogate marker to monitor and adjust antiangiogenic therapy.
机构:
Massachusetts Gen Hosp, Dept Radiat Oncol, Steele Lab, Boston, MA 02114 USAMassachusetts Gen Hosp, Dept Radiat Oncol, Steele Lab, Boston, MA 02114 USA
机构:
Massachusetts Gen Hosp, Dept Radiat Oncol, Steele Lab, Boston, MA 02114 USAMassachusetts Gen Hosp, Dept Radiat Oncol, Steele Lab, Boston, MA 02114 USA